Fig. 2: Targeted DNA sequencing analysis demonstrates a high prevalence of TP53 E285K mutations in UC. | Nature Communications

Fig. 2: Targeted DNA sequencing analysis demonstrates a high prevalence of TP53 E285K mutations in UC.

From: Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer

Fig. 2

a Oncoplot of UC-GENOME bladder tumor samples sequence variant measurements, with annotation tracks for consensus subtype, tumor mutation burden (TMB), and gender. The top 25 genes based on frequency across samples of non-silent variants are shown. Percentages indicate number of tumor samples of total with an identified variant in each respective gene. Gene fusions and the most frequent focal amplifications of those assayed (Methods section) are shown in lower panel. VAF = average variant allele frequency, InDel  = Insertion or deletion, Mb = Megabase. b Number of TP53 E285 mutations by tumor type across TCGA. The percent of the indicated variant within the total number of TP53 mutations for b UC-GENOME, c Imvigor210, d TCGA BLCA, and e TCGA PanCancer. The variants shown are the top 5 most frequently mutated sites plus E285 (if not otherwise present). Source data are provided as a Source Data file.

Back to article page